[go: up one dir, main page]

CN1094620A - The Chinese patent medicine Liu Hua ai huixiangdan of the treatment esophageal carcinoma - Google Patents

The Chinese patent medicine Liu Hua ai huixiangdan of the treatment esophageal carcinoma Download PDF

Info

Publication number
CN1094620A
CN1094620A CN93104343A CN93104343A CN1094620A CN 1094620 A CN1094620 A CN 1094620A CN 93104343 A CN93104343 A CN 93104343A CN 93104343 A CN93104343 A CN 93104343A CN 1094620 A CN1094620 A CN 1094620A
Authority
CN
China
Prior art keywords
radix
patent medicine
chinese patent
treatment
esophageal carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN93104343A
Other languages
Chinese (zh)
Other versions
CN1050045C (en
Inventor
刘学勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN93104343A priority Critical patent/CN1050045C/en
Publication of CN1094620A publication Critical patent/CN1094620A/en
Application granted granted Critical
Publication of CN1050045C publication Critical patent/CN1050045C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A kind of Chinese patent medicine for the treatment of the esophageal carcinoma; the remission rate of the existing treatment by Chinese herbs esophageal carcinoma only 10-40%; this Chinese medicine adopts treating the poisonous disease with poisonous drugs; heat-clearing and toxic substances removing; dissipating phlegm and resolving masses; the Therapeutic Principle of the body resistance strengthening and constitution consolidating; select arsenicum sablimatum for use; Mylabris; Venenum Bufonis; snake venom; Scolopendra; Hirudo; the scorpion tail; Gekko Swinhonis; Moschus; Calculus Bovis; Radix Adenophorae (Radix Glehniae); Radix Ginseng; Radix Pseudostellariae; 14 flavor Chinese medicines such as Cornu Cervi Degelatinatum are made patent medicine; after taking, the patient can effectively kill and wound cancerous cell; strengthen immune function of human body; improve the symptom that the middle and advanced stage patient can not take food; improve the human body resistance against diseases; clinical effective rate reaches 67.59%, takes this medicine simultaneously and does not have obvious toxic-side effects, and is safe and reliable.

Description

The Chinese patent medicine Liu Hua ai huixiangdan of the treatment esophageal carcinoma
The invention belongs to a kind of Chinese patent medicine for the treatment of the esophageal carcinoma.
The esophageal carcinoma is one of common cancer, and mortality rate is higher, and serious harm human life health except that symptomatic treatment, is gone back inefficacy Chinese patent medicine preferably at present.The nearly curative effect of traditional Chinese medicine on esophageal carcinoma during the last ten years obtains certain progress, but show according to the documents and materials statistics, simple remission rate with the treatment by Chinese herbs esophageal carcinoma only can reach 10-40%(and see " Chinese and Western is in conjunction with the oncology " 1989.12 P400-425 pages or leaves), as seen curative effect can not be satisfactory, generally also have simultaneously a problem in esophageal carcinoma therapy: the middle and advanced stage patient is owing to can not take food, cause physical weakness, also influenced therapeutic effect greatly.
The present invention aims to provide the very fast reduction of patient disease of a kind of energy, improve himself resistance against diseases and obtain the pure Chinese medicinal preparation of the treatment esophageal carcinoma of higher curative effect.
The object of the present invention is achieved like this: dosage and the formulation ratio of 100 days each courses of treatment of this Chinese patent medicine are:
Arsenicum sablimatum 9-12g Venenum Bufonis 28-31g snake venom 13-16g
49 Hirudo 85-93g of Mylabris 28-31g Scolopendra
Scorpion tail 12-17g Gekko Swinhonis 200-250g Moschus 1-3g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 100-130g Radix Ginseng 200-250g
Radix Pseudostellariae 200-250g Cornu Cervi Degelatinatum 25-32g
Arsenicum sablimatum wherein, Scolopendra, Hirudo, scorpion tail, Radix Adenophorae (Radix Glehniae) be all earlier through with the processing of water extraction, and Mylabris is earlier through traditional liter refining processing, again with above-mentioned various compositions traditional method decocting, concentrated make Powdered.
We have adopted the prescription therapeutic principle of " treating the poisonous disease with poisonous drugs ", " heat-clearing and toxic substances removing ", " dissipating phlegm and resolving masses ", " the body resistance strengthening and constitution consolidating "; but as the Mylabris in the side, Venenum Bufonis, scorpion tail, Scolopendra, Gekko Swinhonis, arsenicum sablimatum treating the poisonous disease with poisonous drugs, kill and wound cancerous cell; Calculus Bovis, Moschus heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling; Radix Ginseng, Radix Pseudostellariae, Cornu Cervi Degelatinatum strengthening vital QI to eliminate pathogenic factors increase immunologic function.
The part Chinese materia medica tocixity of selecting for use among the we is bigger, in order to reduce its toxicity, and guarantees that fully it kills and wounds the effect of cancerous cell, and this class medicine all through rising processing such as refining or water extraction concentrate, greatly reduces its toxicity, has guaranteed the safety to human body.This medicine is through acute poison test, give 10 white mice dosing times by people's dose 104 multiple doses, observe and do not have death in 6 days, through routine clinical trial surplus in the of 4500 more than 3 years, find no obvious toxic-side effects, and 60% middle and advanced stage patient medication can improve symptom in 7-15 days, became smooth feed by not taking food.
" tumor efficiency common index " with reference to the whole nation " Chinese and Western is in conjunction with the tumor academic conference " in December, 1979 formulation is foundation, 108 routine patient with esophageal carcinoma have been made the clinical efficacy statistical procedures, clinical symptoms is alleviation person's 50 examples fully, part alleviation person 23 examples, and total effective rate is 67.59%.Through 54 of this group patients are followed up a case by regular visits to, above patient's 11 examples of a year and a half of surviving, existence patient's 15 examples more than a year, existence patient's 21 examples more than 6 months, existence patient's 7 examples more than 3 months, mean survival time (MST), prolong 9.6 months, and this medicine also has better curative effect to other digestive tract cancer.
This Chinese medicine can effectively kill and wound cancerous cell, strengthen patient's immunologic function simultaneously, improve the situation that the middle and advanced stage patient can not take food, improve the resistance against diseases of human body, thereby make clinical effective rate reach 67.59%, considerably beyond the average effectiveness level of present other treatment by Chinese herbs esophageal carcinoma, this medicine can also on average prolong survival time of patients more than 9 months, and take this medicine and do not have obvious toxic-side effects, safe and reliable.
The invention will be further described below in conjunction with embodiment.
Embodiment 1: " the Liu Shiization cancer is rejuvenated red " by dosage 100 days per courses of treatment, its proportioning prescription is:
Arsenicum sablimatum 10g Venenum Bufonis 30g snake venom 15g
49 Hirudo 90g of Mylabris 30g Scolopendra
Scorpion tail 15g Gekko Swinhonis 240g Moschus 2g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 120g Radix Ginseng 240g
Radix Pseudostellariae 240g Cornu Cervi Degelatinatum 30g
With arsenicum sablimatum, Scolopendra, Hirudo, scorpion tail, Radix Adenophorae (Radix Glehniae) water extraction wherein, Mylabris is processed with traditional smelting method that rises, again with mentioned component medicine water boiling concentration, refinement, finally making the about 420g of powdered drug packs in 1200 capsules, every about 0.35 gram, every day three times when taking, each four, 100 days courses of treatment.
Embodiment 2: by dosage 100 days per courses of treatment, its formulation ratio is:
Arsenicum sablimatum 9g Venenum Bufonis 28g snake venom 13g
49 Hirudo 85g of Mylabris 28g Scolopendra
Scorpion tail 12g Gekko Swinhonis 200g Moschus 1g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 100g Radix Ginseng 200g
Radix Pseudostellariae 200g Cornu Cervi Degelatinatum 25g
Processing method is the same.
Embodiment 3: by dosage 100 days per courses of treatment, its formulation ratio is:
Arsenicum sablimatum 12g Venenum Bufonis 31g snake venom 16g
Mylabris 31g Scolopendra 49g Hirudo 93g
Scorpion tail 17g Gekko Swinhonis 250g Moschus 3g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 130g Radix Ginseng 250g
Radix Pseudostellariae 240g Cornu Cervi Degelatinatum 32g
Processing method is the same.

Claims (2)

1, a kind of Chinese patent medicine for the treatment of the esophageal carcinoma is characterized in that: dosage and the formulation ratio of 100 days each courses of treatment of described Chinese patent medicine are:
Arsenicum sablimatum 9-12g Venenum Bufonis 28-31g snake venom 13-16g
49 Hirudo 85-93g of Mylabris 28-31g Scolopendra
Scorpion tail 12-17g Gekko Swinhonis 200-250g Moschus 1-3g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 100-130g Radix Ginseng 200-250g
Radix Pseudostellariae 200-250g Cornu Cervi Degelatinatum 25-32g
Arsenicum sablimatum wherein, Scolopendra, Hirudo, scorpion tail, Radix Adenophorae (Radix Glehniae) be all earlier through with the processing of water extraction, and Mylabris is earlier through traditional liter refining processing, again with the various compositions of above-mentioned prescription traditional method decocting, concentrated make Powdered.
2, Chinese patent medicine as claimed in claim 1 is characterized in that: dosage and the formulation ratio of 100 days each courses of treatment of described Chinese patent medicine are:
Arsenicum sablimatum 10g Venenum Bufonis 30g snake venom 15g
49 Hirudo 90g of Mylabris 30g Scolopendra
Scorpion tail 15g Gekko Swinhonis 240g Moschus 2g
Calculus Bovis 1g Radix Adenophorae (Radix Glehniae) 120g Radix Ginseng 240g
Radix Pseudostellariae 240g Cornu Cervi Degelatinatum 30g
CN93104343A 1993-04-17 1993-04-17 Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus Expired - Fee Related CN1050045C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN93104343A CN1050045C (en) 1993-04-17 1993-04-17 Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN93104343A CN1050045C (en) 1993-04-17 1993-04-17 Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus

Publications (2)

Publication Number Publication Date
CN1094620A true CN1094620A (en) 1994-11-09
CN1050045C CN1050045C (en) 2000-03-08

Family

ID=4985145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93104343A Expired - Fee Related CN1050045C (en) 1993-04-17 1993-04-17 Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus

Country Status (1)

Country Link
CN (1) CN1050045C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114422C (en) * 2000-03-13 2003-07-16 徐忠廷 Anti-cancer Chinese-medicinal pill
CN102406841A (en) * 2011-12-02 2012-04-11 龚定军 Traditional Chinese medicine for treating tumor
CN102416083A (en) * 2011-12-12 2012-04-18 许从玉 A kind of pharmaceutical composition for treating esophageal cancer
CN101347459B (en) * 2008-09-10 2013-01-02 刘皇琼 Medicine for treating cancer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114422C (en) * 2000-03-13 2003-07-16 徐忠廷 Anti-cancer Chinese-medicinal pill
CN101347459B (en) * 2008-09-10 2013-01-02 刘皇琼 Medicine for treating cancer
CN102406841A (en) * 2011-12-02 2012-04-11 龚定军 Traditional Chinese medicine for treating tumor
CN102416083A (en) * 2011-12-12 2012-04-18 许从玉 A kind of pharmaceutical composition for treating esophageal cancer
CN102416083B (en) * 2011-12-12 2012-07-18 许从玉 Medicinal composition for treating esophagus cancer

Also Published As

Publication number Publication date
CN1050045C (en) 2000-03-08

Similar Documents

Publication Publication Date Title
CN1210047C (en) Medicine for treating cold and preparation method thereof
CN100382839C (en) Chinese-medicinal composition for treating coronary heart disease
CN1129130A (en) Medicament for treatment of cervical spondylopathy
CN1050045C (en) Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus
CN1507884A (en) Traditional Chinese medicine powder and decoction composition for treating cancer
CN1056755C (en) Medicine of curing hepatitis
CN100411666C (en) Broad-specturm medicine for treating snake venom poisoning
CN1255150C (en) Chinese medicine preparation for curing hyperosteogeny and its preparation method
CN1302799C (en) Oral Chinese medicinal composition for treating virus myocarditis
CN1616041A (en) Chinese medicine composition for treating chronic ulcerative colitis
CN1313138C (en) Chinese medicine preparation treating Parkinson's syndrome
CN1055014C (en) Medicine powder for curing hepatitis B
CN106344680B (en) A kind of Chinese medicine composition with wind and relieving paralysis effect of dispelling and preparation method thereof
CN1537559A (en) Traditional Chinese medicine for treating AIDS
CN1060048C (en) Snake spirit for rheumatism and its preparation
RU2133096C1 (en) Biologically active food addition "pari" and method of its use
CN1245184C (en) A kind of traditional Chinese medicine preparation for treating insomnia and preparation method thereof
CN101194997A (en) Chinese medicine preparation for treating AIDS method for preparing the same
CN1093421C (en) Process for preparing snuff to treat hepatitis B
CN1177592C (en) Application of Radix Radix Radix Radix Extract Total Saponins in the Preparation of Drugs for Treating Myocarditis
CN1824020A (en) Medicine for treating coronary heart disease and preparation method thereof
CN1292765C (en) Pharmaceutical composition, its preparation process and usage
CN1087612C (en) Anti-cancer compound preparation
CN1063074C (en) Chinese herbs injection for treating oncoma (cancer) and preparation method
CN1200289A (en) Sanhua xietingye liquid medicine for treating diarrhea made of three flowers

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee